Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM5 | P41594 | 3/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | BRCA1 | P38398 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | ATM | Q13315 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.37 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.37 |
| ▸ | NOS3 | P29474 | 1/20 | 0.36 |
| ▸ | NOS1 | P29475 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | GSK3A | P49840 | 1/20 | 0.35 |
| ▸ | GSK3B | P49841 | 1/20 | 0.35 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16609886 | 0.94 | NOS1 (0.42) | GRM5MEN1KMT2AMAPK1NOS3 | |
| SCHEMBL16609902 | 0.94 | NOS1 (0.42) | GRM5MEN1KMT2AMAPK1NOS3 | |
| SCHEMBL761295 | 0.94 | NOS1 (0.42) | GRM5MEN1KMT2AMAPK1NOS3 | |
| SCHEMBL13208002 | 0.82 | ADORA2A (0.42) | ADORA3ADORA2ANOS3NOS1GSK3A | |
| SCHEMBL23714592 | 0.77 | MAPK1 (0.43) | MAPK1ADORA2ANOS3NOS1 | |
| SCHEMBL13455158 | 0.77 | NPY5R (0.43) | MAPK1ADORA2ANOS3NOS1 | |
| SCHEMBL18390617 | 0.75 | HTR2A (0.42) | — | |
| SCHEMBL14826661 | 0.75 | LMNA (0.36) | MEN1MAPTBRCA1KMT2AATM | |
| SCHEMBL15919806 | 0.75 | LMNA (0.36) | MEN1MAPTBRCA1KMT2AATM | |
| SCHEMBL24736661 | 0.75 | MAPT (0.36) | GRM5MEN1MAPTBRCA1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240058316-A1 | PRODRUG OF A PHENOLIC TRPV1 AGONIST FOR THE TREATMENT OF PAIN | Concentric Analgesics, Inc. | 2024-02-22 | — | — | US | disclosed |
| US-20240051921-A1 | CRYSTALLINE FORM OF A PHENOLIC TRPV1 AGONIST PRODRUG | Concentric Analgesics, Inc. | 2024-02-15 | — | — | US | disclosed |
| US-20240050421-A1 | PHARMACEUTICAL FORMULATIONS OF A PHENOLIC TRPV1 AGONIST PRODRUG | Concentric Analgesics, Inc. | 2024-02-15 | — | — | US | disclosed |
| WO-2023192375-A1 | HSD17B13 INHIBITORS AND USES THEREOF | FL2022-001, INC. (US) | 2023-10-05 | — | — | WO | disclosed |
| WO-2023274390-A1 | BRUTON'S TYROSINE KINASE AND MUTANT DEGRADER, COMPOSITION AND APPLICATION THEREOF | 杭州和正医药有限公司 | 2023-01-05 | — | — | WO | disclosed |
| US-20220387395-A1 | UREA, AMIDE, AND SUBSTITUTED HETEROARYL COMPOUNDS FOR CBL-B INHIBITION | NURIX THERAPEUTICS, INC. | 2022-12-08 | — | — | US | disclosed |
| US-11464767-B2 | Prodrugs of phenolic TRPV1 agonists in combination with local anesthetics and vasoconstrictors for improved local anesthesia | Concentric Analgesics, Inc. (US) | 2022-10-11 | — | — | US | disclosed |
| WO-2022132646-A1 | CRYSTALLINE FORM OF A PHENOLIC TRPV1 AGONIST PRODRUG | Concentric Analgesics, Inc. (US) | 2022-06-23 | — | — | WO | disclosed |
| WO-2022132650-A1 | PRODRUG OF A PHENOLIC TRPV1 AGONIST FOR THE TREATMENT OF PAIN | Concentric Analgesics, Inc. (US) | 2022-06-23 | — | — | WO | disclosed |
| WO-2022132649-A1 | PHARMACEUTICAL FORMULATIONS OF A PHENOLIC TRPV1 AGONIST PRODRUG | Concentric Analgesics, Inc. (US) | 2022-06-23 | — | — | WO | disclosed |
| US-20210008050-A1 | PRODRUGS OF PHENOLIC TRPV1 AGONISTS IN COMBINATION WITH LOCAL ANESTHETICS AND VASOCONSTRICTORS FOR IMPROVED LOCAL ANESTHESIA | Concentric Analgesics, Inc. | 2021-01-14 | — | — | US | disclosed |
| US-20210008050-A1 | PRODRUGS OF PHENOLIC TRPV1 AGONISTS IN COMBINATION WITH LOCAL ANESTHETICS AND VASOCONSTRICTORS FOR IMPROVED LOCAL ANESTHESIA | Concentric Analgesics, Inc. | 2021-01-14 | — | — | US | disclosed |
| US-10821105-B2 | Prodrugs of phenolic TRPV1 agonists in combination with local anesthetics and vasoconstrictors for improved local anesthesia | Concentric Analgesics, Inc. (US) | 2020-11-03 | — | — | US | disclosed |
| US-10821105-B2 | Prodrugs of phenolic TRPV1 agonists in combination with local anesthetics and vasoconstrictors for improved local anesthesia | Concentric Analgesics, Inc. (US) | 2020-11-03 | — | — | US | disclosed |
| US-20190216787-A1 | PRODRUGS OF PHENOLIC TRPV1 AGONISTS IN COMBINATION WITH LOCAL ANESTHETICS AND VASOCONSTRICTORS FOR IMPROVED LOCAL ANESTHESIA | Concentric Analgesics, Inc. | 2019-07-18 | — | — | US | disclosed |
| US-20190216787-A1 | PRODRUGS OF PHENOLIC TRPV1 AGONISTS IN COMBINATION WITH LOCAL ANESTHETICS AND VASOCONSTRICTORS FOR IMPROVED LOCAL ANESTHESIA | Concentric Analgesics, Inc. | 2019-07-18 | — | — | US | disclosed |
| EP-3463576-A1 | PRODRUGS OF PHENOLIC TRPV1 AGONISTS IN COMBINATION WITH LOCAL ANESTHETICS AND VASOCONSTRICTORS FOR IMPROVED LOCAL ANESTHESIA | Concentric Analgesics, Inc. (US) | 2019-04-10 | — | — | EP | disclosed |
| WO-2017205534-A1 | PRODRUGS OF PHENOLIC TRPV1 AGONISTS IN COMBINATION WITH LOCAL ANESTHETICS AND VASOCONSTRICTORS FOR IMPROVED LOCAL ANESTHESIA | Concentric Analgesics, Inc. (US) | 2017-11-30 | — | — | WO | disclosed |
| WO-2017205534-A1 | PRODRUGS OF PHENOLIC TRPV1 AGONISTS IN COMBINATION WITH LOCAL ANESTHETICS AND VASOCONSTRICTORS FOR IMPROVED LOCAL ANESTHESIA | Concentric Analgesics, Inc. (US) | 2017-11-30 | — | — | WO | disclosed |
| US-20120135997-A1 | PHARMACEUTICAL COMPOSITION COMPRISING A LACTAM OR BENZENESULFONAMIDE COMPOUND | SHIONOGI & CO., LTD. (JP) | 2012-05-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240051921-A1 | CRYSTALLINE FORM OF A PHENOLIC TRPV1 AGONIST PRODRUG | TRPV1, TRPV4, TRPV3 | GRM5 328/4885MEN1 3988/4885MAPT 655/4885 |
| US-20120135997-A1 | PHARMACEUTICAL COMPOSITION COMPRISING A LACTAM OR BENZENESULFONAMIDE COMPOUND | BACE1, STS, APP | GRM5 2955/4885MEN1 4518/4885MAPT 53/4885 |
| US-20240050421-A1 | PHARMACEUTICAL FORMULATIONS OF A PHENOLIC TRPV1 AGONIST PRODRUG | TRPV1, TRPV3, TRPV2 | GRM5 1186/4885MEN1 4630/4885MAPT 1384/4885 |
| US-20210008050-A1 | PRODRUGS OF PHENOLIC TRPV1 AGONISTS IN COMBINATION WITH LOCAL ANESTHETICS AND VASOCONSTRICTORS FOR IMPROVED LOCAL ANESTHESIA | TRPV1, TRPV4, TRPV2 | GRM5 766/4885MEN1 4787/4885MAPT 2411/4885 |
| US-10821105-B2 | Prodrugs of phenolic TRPV1 agonists in combination with local anesthetics and vasoconstrictors for improved local anesthesia | TRPV1, TRPV4, TRPV2 | GRM5 766/4885MEN1 4787/4885MAPT 2411/4885 |
| US-11464767-B2 | Prodrugs of phenolic TRPV1 agonists in combination with local anesthetics and vasoconstrictors for improved local anesthesia | TRPV1, TRPV4, TRPV2 | GRM5 766/4885MEN1 4787/4885MAPT 2411/4885 |
| US-20220387395-A1 | UREA, AMIDE, AND SUBSTITUTED HETEROARYL COMPOUNDS FOR CBL-B INHIBITION | CBLB, CBL, CBLC | GRM5 4476/4885MEN1 4354/4885MAPT 1811/4885 |
| US-20190216787-A1 | PRODRUGS OF PHENOLIC TRPV1 AGONISTS IN COMBINATION WITH LOCAL ANESTHETICS AND VASOCONSTRICTORS FOR IMPROVED LOCAL ANESTHESIA | TRPV1, TRPV4, TRPV2 | GRM5 766/4885MEN1 4787/4885MAPT 2411/4885 |
| US-20240058316-A1 | PRODRUG OF A PHENOLIC TRPV1 AGONIST FOR THE TREATMENT OF PAIN | TRPV1, OPRL1, TRPV2 | GRM5 810/4885MEN1 4870/4885MAPT 2211/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.